The global chronotherapy services market size is calculated at USD 895.89 million in 2025 and is forecasted to reach around USD 1,314.27 million by 2034, accelerating at a CAGR of 4.35% from 2025 to 2034. The North America market size surpassed USD 356.29 million in 2024 and is expanding at a CAGR of 4.35% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Chronotherapy Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Chronotherapy Services Market, by Therapy Area
8.1.1. Sleep Disorders
8.1.1.1. Market Revenue and Forecast
8.1.2. Psychiatric Conditions (e.g., depression, bipolar disorder)
8.1.2.1. Market Revenue and Forecast
8.1.3. Oncology (e.g., circadian-timed chemotherapy)
8.1.3.1. Market Revenue and Forecast
8.1.4. Hypertension and Cardiovascular Disorders
8.1.4.1. Market Revenue and Forecast
8.1.5. Metabolic and Endocrine Disorders (e.g., diabetes, obesity)
8.1.5.1. Market Revenue and Forecast
8.1.6. Neurological Conditions (e.g., Alzheimer's, Parkinson's)
8.1.6.1. Market Revenue and Forecast
8.1.7. Chronopharmacology in Pain Management
8.1.7.1. Market Revenue and Forecast
9.1. Chronotherapy Services Market, by Service Type
9.1.1. Chronotherapy Scheduling & Optimization Services
9.1.1.1. Market Revenue and Forecast
9.1.2. Diagnostic Services (Actigraphy, Salivary Cortisol, Melatonin Profiles)
9.1.2.1. Market Revenue and Forecast
9.1.3. Behavioral & Cognitive Chronotherapy Programs
9.1.3.1. Market Revenue and Forecast
9.1.4. Light Therapy and Circadian Realignment Programs
9.1.4.1. Market Revenue and Forecast
9.1.5. Remote Monitoring & Wearable-Based Services
9.1.5.1. Market Revenue and Forecast
9.1.6. Pharmacological Timing Consultations
9.1.6.1. Market Revenue and Forecast
10.1. Chronotherapy Services Market, by Delivery Mode
10.1.1. Clinic-Based Services
10.1.1.1. Market Revenue and Forecast
10.1.2. Home-Based Services
10.1.2.1. Market Revenue and Forecast
10.1.3. Telehealth/Virtual Chronotherapy Consultations
10.1.3.1. Market Revenue and Forecast
10.1.4. Hospital-Based Services (within oncology or psychiatry departments)
10.1.4.1. Market Revenue and Forecast
11.1. Chronotherapy Services Market, by Patient Type
11.1.1. Adults (18–65 years)
11.1.1.1. Market Revenue and Forecast
11.1.2. Pediatrics and Adolescents
11.1.2.1. Market Revenue and Forecast
11.1.3. Geriatric Patients
11.1.3.1. Market Revenue and Forecast
12.1. Chronotherapy Services Market, by End Use
12.1.1. Sleep Clinics & Chronobiology Specialty Centers
12.1.1.1. Market Revenue and Forecast
12.1.2. Hospitals & Academic Medical Centers
12.1.2.1. Market Revenue and Forecast
12.1.3. Behavioral Health Clinics
12.1.3.1. Market Revenue and Forecast
12.1.4. Home Healthcare Providers
12.1.4.1. Market Revenue and Forecast
12.1.5. Corporate Wellness & Occupational Health Programs
12.1.5.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy Area
13.1.2. Market Revenue and Forecast, by Service Type
13.1.3. Market Revenue and Forecast, by Delivery Mode
13.1.4. Market Revenue and Forecast, by Patient Type
13.1.5. Market Revenue and Forecast, by End Use
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy Area
13.1.6.2. Market Revenue and Forecast, by Service Type
13.1.6.3. Market Revenue and Forecast, by Delivery Mode
13.1.6.4. Market Revenue and Forecast, by Patient Type
13.1.6.5. Market Revenue and Forecast, by End Use
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy Area
13.1.7.2. Market Revenue and Forecast, by Service Type
13.1.7.3. Market Revenue and Forecast, by Delivery Mode
13.1.7.4. Market Revenue and Forecast, by Patient Type
13.1.7.5. Market Revenue and Forecast, by End Use
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy Area
13.2.2. Market Revenue and Forecast, by Service Type
13.2.3. Market Revenue and Forecast, by Delivery Mode
13.2.4. Market Revenue and Forecast, by Patient Type
13.2.5. Market Revenue and Forecast, by End Use
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy Area
13.2.6.2. Market Revenue and Forecast, by Service Type
13.2.6.3. Market Revenue and Forecast, by Delivery Mode
13.2.7. Market Revenue and Forecast, by Patient Type
13.2.8. Market Revenue and Forecast, by End Use
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy Area
13.2.9.2. Market Revenue and Forecast, by Service Type
13.2.9.3. Market Revenue and Forecast, by Delivery Mode
13.2.10. Market Revenue and Forecast, by Patient Type
13.2.11. Market Revenue and Forecast, by End Use
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy Area
13.2.12.2. Market Revenue and Forecast, by Service Type
13.2.12.3. Market Revenue and Forecast, by Delivery Mode
13.2.12.4. Market Revenue and Forecast, by Patient Type
13.2.13. Market Revenue and Forecast, by End Use
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy Area
13.2.14.2. Market Revenue and Forecast, by Service Type
13.2.14.3. Market Revenue and Forecast, by Delivery Mode
13.2.14.4. Market Revenue and Forecast, by Patient Type
13.2.15. Market Revenue and Forecast, by End Use
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy Area
13.3.2. Market Revenue and Forecast, by Service Type
13.3.3. Market Revenue and Forecast, by Delivery Mode
13.3.4. Market Revenue and Forecast, by Patient Type
13.3.5. Market Revenue and Forecast, by End Use
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy Area
13.3.6.2. Market Revenue and Forecast, by Service Type
13.3.6.3. Market Revenue and Forecast, by Delivery Mode
13.3.6.4. Market Revenue and Forecast, by Patient Type
13.3.7. Market Revenue and Forecast, by End Use
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy Area
13.3.8.2. Market Revenue and Forecast, by Service Type
13.3.8.3. Market Revenue and Forecast, by Delivery Mode
13.3.8.4. Market Revenue and Forecast, by Patient Type
13.3.9. Market Revenue and Forecast, by End Use
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy Area
13.3.10.2. Market Revenue and Forecast, by Service Type
13.3.10.3. Market Revenue and Forecast, by Delivery Mode
13.3.10.4. Market Revenue and Forecast, by Patient Type
13.3.10.5. Market Revenue and Forecast, by End Use
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy Area
13.3.11.2. Market Revenue and Forecast, by Service Type
13.3.11.3. Market Revenue and Forecast, by Delivery Mode
13.3.11.4. Market Revenue and Forecast, by Patient Type
13.3.11.5. Market Revenue and Forecast, by End Use
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy Area
13.4.2. Market Revenue and Forecast, by Service Type
13.4.3. Market Revenue and Forecast, by Delivery Mode
13.4.4. Market Revenue and Forecast, by Patient Type
13.4.5. Market Revenue and Forecast, by End Use
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy Area
13.4.6.2. Market Revenue and Forecast, by Service Type
13.4.6.3. Market Revenue and Forecast, by Delivery Mode
13.4.6.4. Market Revenue and Forecast, by Patient Type
13.4.7. Market Revenue and Forecast, by End Use
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy Area
13.4.8.2. Market Revenue and Forecast, by Service Type
13.4.8.3. Market Revenue and Forecast, by Delivery Mode
13.4.8.4. Market Revenue and Forecast, by Patient Type
13.4.9. Market Revenue and Forecast, by End Use
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy Area
13.4.10.2. Market Revenue and Forecast, by Service Type
13.4.10.3. Market Revenue and Forecast, by Delivery Mode
13.4.10.4. Market Revenue and Forecast, by Patient Type
13.4.10.5. Market Revenue and Forecast, by End Use
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy Area
13.4.11.2. Market Revenue and Forecast, by Service Type
13.4.11.3. Market Revenue and Forecast, by Delivery Mode
13.4.11.4. Market Revenue and Forecast, by Patient Type
13.4.11.5. Market Revenue and Forecast, by End Use
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy Area
13.5.2. Market Revenue and Forecast, by Service Type
13.5.3. Market Revenue and Forecast, by Delivery Mode
13.5.4. Market Revenue and Forecast, by Patient Type
13.5.5. Market Revenue and Forecast, by End Use
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy Area
13.5.6.2. Market Revenue and Forecast, by Service Type
13.5.6.3. Market Revenue and Forecast, by Delivery Mode
13.5.6.4. Market Revenue and Forecast, by Patient Type
13.5.7. Market Revenue and Forecast, by End Use
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy Area
13.5.8.2. Market Revenue and Forecast, by Service Type
13.5.8.3. Market Revenue and Forecast, by Delivery Mode
13.5.8.4. Market Revenue and Forecast, by Patient Type
13.5.8.5. Market Revenue and Forecast, by End Use
14.1. Cenegenics
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Chronobiology.com (Swiss BioHealth)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. SleepRate
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Cereset
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Nightingale Health
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Ebb Therapeutics
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. MindMaze
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Chrono Therapeutics
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. The Circadian Sleep Disorders Network
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Headspace Health
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description